7:12 AM ET
8-K
Clinical Trial Data
Alkermes Clinical Trial Data
Alkermes announced positive topline results from a Phase 1b proof-of-concept study for ALKS 7290, a novel orexin 2 receptor agonist for the treatment of ADHD. The study demonstrated clinically meaningful improvements in ADHD symptoms as measured by the AISRS and CGI-S scales, marking the first clinical evidence of an orexin agonist's efficacy in ADHD. A Phase 2 study is currently enrolling with data expected in 2027.